Auris Medical Holding AG (EARS) Upgraded at Zacks Investment Research
Zacks Investment Research upgraded shares of Auris Medical Holding AG (NASDAQ:EARS) from a hold rating to a buy rating in a research note published on Wednesday morning. The firm currently has $0.75 target price on the biotechnology company’s stock.
According to Zacks, “Auris Medical Holding AG is a biopharmaceutical company. It focuses on developing therapies for the treatment of hearing loss and tinnitus. The Company has two projects in advanced clinical development: AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. Auris Medical Holding AG is headquartered in Zug, Switzerland. “
Several other brokerages have also commented on EARS. ValuEngine lowered Auris Medical Holding AG from a sell rating to a strong sell rating in a research report on Friday, June 2nd. Roth Capital reissued a buy rating and set a $5.00 price objective on shares of Auris Medical Holding AG in a research report on Saturday, July 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus price target of $3.25.
Auris Medical Holding AG (EARS) traded up 14.1417% on Wednesday, reaching $0.7248. 1,546,487 shares of the company’s stock traded hands. The firm’s 50 day moving average price is $0.77 and its 200 day moving average price is $0.76. Auris Medical Holding AG has a 12 month low of $0.60 and a 12 month high of $2.09. The company’s market cap is $32.13 million.
Auris Medical Holding AG (NASDAQ:EARS) last released its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.09. On average, equities analysts expect that Auris Medical Holding AG will post ($0.63) EPS for the current fiscal year.
A number of institutional investors have recently made changes to their positions in the stock. UBS Oconnor LLC purchased a new position in shares of Auris Medical Holding AG during the first quarter valued at approximately $909,000. Perceptive Advisors LLC bought a new position in Auris Medical Holding AG during the first quarter valued at about $368,000. Sabby Management LLC bought a new position in Auris Medical Holding AG during the first quarter valued at about $133,000. Finally, Virtu KCG Holdings LLC bought a new position in Auris Medical Holding AG during the second quarter valued at about $101,000. 28.41% of the stock is owned by institutional investors and hedge funds.
About Auris Medical Holding AG
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related companies with Analyst Ratings Network's FREE daily email newsletter.